Silverfin false false 31/05/2024 25/05/2023 31/05/2024 Dr L Moore 25/05/2023 Mrs M Moore 25/05/2023 17 February 2025 no description of principal activity 14894823 2024-05-31 14894823 bus:Director1 2024-05-31 14894823 bus:Director2 2024-05-31 14894823 core:CurrentFinancialInstruments 2024-05-31 14894823 core:ShareCapital 2024-05-31 14894823 core:RetainedEarningsAccumulatedLosses 2024-05-31 14894823 2023-05-25 2024-05-31 14894823 bus:FilletedAccounts 2023-05-25 2024-05-31 14894823 bus:SmallEntities 2023-05-25 2024-05-31 14894823 bus:AuditExemptWithAccountantsReport 2023-05-25 2024-05-31 14894823 bus:PrivateLimitedCompanyLtd 2023-05-25 2024-05-31 14894823 bus:Director1 2023-05-25 2024-05-31 14894823 bus:Director2 2023-05-25 2024-05-31 14894823 core:CurrentFinancialInstruments 2023-05-25 2024-05-31 iso4217:GBP xbrli:pure

Company No: 14894823 (England and Wales)

CLINICAL INFECTION CONSULTING LIMITED

Unaudited Financial Statements
For the financial period from 25 May 2023 to 31 May 2024
Pages for filing with the registrar

CLINICAL INFECTION CONSULTING LIMITED

Unaudited Financial Statements

For the financial period from 25 May 2023 to 31 May 2024

Contents

CLINICAL INFECTION CONSULTING LIMITED

STATEMENT OF FINANCIAL POSITION

As at 31 May 2024
CLINICAL INFECTION CONSULTING LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 May 2024
Note 31.05.2024
£
Current assets
Debtors 3 11,488
Cash at bank and in hand 224,423
235,911
Creditors: amounts falling due within one year 4 ( 61,154)
Net current assets 174,757
Total assets less current liabilities 174,757
Net assets 174,757
Capital and reserves
Called-up share capital 100
Profit and loss account 174,657
Total shareholders' funds 174,757

For the financial period ending 31 May 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Clinical Infection Consulting Limited (registered number: 14894823) were approved and authorised for issue by the Board of Directors. They were signed on its behalf by:

Dr L Moore
Director

17 February 2025

CLINICAL INFECTION CONSULTING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 25 May 2023 to 31 May 2024
CLINICAL INFECTION CONSULTING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 25 May 2023 to 31 May 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Clinical Infection Consulting Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 8 The Courtyard Wyncolls Road, Severalls Industrial Park, Colchester, CO4 9PE, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Reporting period length

The company's first accounting period is from incorporation on 25 May 2023 to 31 May 2024.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Statement of Financial Position date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Statement of Financial Position date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

2. Employees

Period from
25.05.2023 to
31.05.2024
Number
Monthly average number of persons employed by the Company during the period, including directors 2

3. Debtors

31.05.2024
£
Trade debtors 8,948
Prepayments 2,540
11,488

4. Creditors: amounts falling due within one year

31.05.2024
£
Amounts owed to directors 1,329
Accruals 1,800
Corporation tax 58,025
61,154

There are no amounts included above in respect of which any security has been given by the company.